Nicotinamide Riboside Attenuates inflammation in a mouse model of psoriasis

Psoriasis is a chronic inflammatory skin disease driven by dysregulated immune responses, in which IL–17–producing T cells play a central role. Nicotinamide riboside (NR), a precursor of NAD+, has recently emerged as a potential immunomodulatory intervention. Previous studies have shown that NR preferentially suppresses Th17 responsiveness in CD4+ T cells from individuals with psoriasis, but whether NR can attenuate psoriasiform inflammation in vivo remains poorly defined. Here, we investigated the effects of NR supplementation in a mouse model of imiquimod (IMQ)–induced psoriasiform skin inflammation. NR treatment markedly attenuated IMQ–induced splenomegaly and reduced epidermal thickening, indicating an improvement of both systemic and cutaneous inflammatory manifestations. Flow cytometric analysis of skin infiltrates revealed a reduction in inflammatory myeloid populations, including neutrophils and inflammatory monocyte–macrophages, together with a pronounced decrease in dermal TCR γδ and CD4+ T cells. Consistent with these findings, CD4+ T cells isolated from IMQ-treated mice displayed increased IL–17A production following ex vivo TCR stimulation, which was significantly reduced by NR supplementation in a dose-dependent manner. IFNγ and IL–4 responses were not significantly altered by NR in this setting. Furthermore, NR suppressed IL–17A production in Th17–polarized CD4+ T cells, while leaving Th1 and Th2 responses largely unaffected. Together, these findings show that NR treatment attenuates IMQ-induced psoriasiform skin inflammation in vivo and preferentially modulates IL–17A–associated CD4⁺ T–cell responses. The accompanying reduction in dermal γδ T–cell numbers suggests that NR may also influence innate-like T–cell populations involved in cutaneous inflammation, providing experimental evidence for NAD+ boosting as a potential immunomodulatory strategy in psoriasis.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.13.766424
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Nicotinamide Riboside Attenuates inflammation in a mouse model of psoriasis

Marı́a N. Navarro, Javier Traba, Aurea Oliva, Michael N. Sack et al.
2 links
bioRxiv (Cold Spring Harbor Laboratory)
Psoriasis: Treatment and Pathogenesis
preprint

Nicotinamide Riboside Attenuates inflammation in a mouse model of psoriasis

Marı́a N. Navarro, Javier Traba, Aurea Oliva, Michael N. Sack, J.S. Yebra, I. Cayuela, Yara Cuesta
preprint en

Abstract

Psoriasis is a chronic inflammatory skin disease driven by dysregulated immune responses, in which IL–17–producing T cells play a central role. Nicotinamide riboside (NR), a precursor of NAD+, has recently emerged as a potential immunomodulatory intervention. Previous studies have shown that NR preferentially suppresses Th17 responsiveness in CD4+ T cells from individuals with psoriasis, but whether NR can attenuate psoriasiform inflammation in vivo remains poorly defined. Here, we investigated the effects of NR supplementation in a mouse model of imiquimod (IMQ)–induced psoriasiform skin inflammation. NR treatment markedly attenuated IMQ–induced splenomegaly and reduced epidermal thickening, indicating an improvement of both systemic and cutaneous inflammatory manifestations. Flow cytometric analysis of skin infiltrates revealed a reduction in inflammatory myeloid populations, including neutrophils and inflammatory monocyte–macrophages, together with a pronounced decrease in dermal TCR γδ and CD4+ T cells. Consistent with these findings, CD4+ T cells isolated from IMQ-treated mice displayed increased IL–17A production following ex vivo TCR stimulation, which was significantly reduced by NR supplementation in a dose-dependent manner. IFNγ and IL–4 responses were not significantly altered by NR in this setting. Furthermore, NR suppressed IL–17A production in Th17–polarized CD4+ T cells, while leaving Th1 and Th2 responses largely unaffected. Together, these findings show that NR treatment attenuates IMQ-induced psoriasiform skin inflammation in vivo and preferentially modulates IL–17A–associated CD4⁺ T–cell responses. The accompanying reduction in dermal γδ T–cell numbers suggests that NR may also influence innate-like T–cell populations involved in cutaneous inflammation, providing experimental evidence for NAD+ boosting as a potential immunomodulatory strategy in psoriasis.

bioRxiv (Cold Spring Harbor Laboratory)
University College Cork (IE), Centro de Biología Molecular Severo Ochoa (ES), Universidad Autónoma de Madrid (ES)
Office of Dietary Supplements, Comunidad de Madrid, Centro de Biología Molecular Severo Ochoa, National Institutes of Health, European Regional Development Fund, Agencia Estatal de Investigación, European Social Fund
Good health and well-being
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon